BCRX — BioCryst Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.05bn
- $2.52bn
- $874.84m
Brief: Biocryst Pharmaceuticals Increases Wholesale Acquisition Cost For Orladeyo To $44,484.33 Per 28-Day Pack
Brief: Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BioCryst Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: BioCryst Reports Q3 2024 Financial Results And Provides Business Update
Brief: BioCryst Pharmaceuticals Q3 EPS USD -0.07 Vs. IBES Estimate USD -0.06
Intellia falls as mid-stage data from gene therapy study fails to impress
Australia's Island Pharmaceuticals jumps on acquisition of antiviral molecule
U.S. RESEARCH ROUNDUP- Actinium Pharmaceuticals, Albemarle, ArcBest
BioCryst Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: BioCryst Pharmaceuticals Q2 EPS USD -0.06 Vs. IBES Estimate USD -0.17
BioCryst Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Island Pharmaceuticals Signs Non-Binding Term Sheet With Biocryst
Brief: Orladeyo® (Berotralstat) Approved In Mexico
U.S. RESEARCH ROUNDUP- ServiceNow, Ulta Beauty, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-GoDaddy, Walt Disney, Aerovironment
U.S. STOCKS ON THE MOVE-NAPCO Security Technologies, Outset Medical, US energy sector
BioCryst Pharmaceuticals Inc reports results for the quarter ended in January - Earnings Summary
U.S. STOCKS ON THE MOVE-U.S. Steel, Freshpet, oil stocks
U.S. STOCKS ON THE MOVE-Paramount, Occidental Petroleum, Perficient